2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4936 Clinical efficacy and influencing factors of standard immunosuppressive treatment combined with thrombopoietin receptor agonists in the treatment of pediatric acquired severe aplastic anemia

Hui Lv, N/A, Yang lan2, Li Zhang3, Ye Guo4, Yao Zou5, Yumei Chen6, shuchun wang7, Wenyu Yang8, Xiaojuan Chen9, Lixian Chang, MD10, Xiaofan Zhu, MD11
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China

Background   Acquired aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome characterized by pancytopenia and life-threatening complications including hemorrhage, infection, and severe anemia. Standard immunosuppressive treatment (IST, ATG/ALG) can achieve hematologic response in approximately 70% of patients, among whom 10–30% suffer from subsequent relapse, highlighting the unmet need for further improvement in therapeutic efficacy. The clinical evidence for thrombopoietin receptor agonists (TPO-RA) combined with IST in pediatric patients remains insufficient and controversial. This study aimed to evaluate the efficacy and prognostic factors associated with TPO-RA in combination with IST as a first-line therapy for children with acquired severe aplastic anemia (SAA).

Methods   We conducted a retrospective study to analyze the clinical characteristics and prognosis of 31 pediatric patients with severe aplastic anemia (SAA) who received IST combined with TPO-RA therapy (TPO-RA group) at our center between January 1, 2015 and December 31, 2025. Using propensity score matching (PSM) based on age, sex, and disease severity, we compared these patients with 53 pediatric SAA patients treated with IST alone during the same period (IST group).

Results  The TPO-RA group consisted of patients treated with eltrombopag (n=10), hetrombopag (n=10), avatrombopag (n=10), and romiplostim (n=1), median time between IST onset and TPO-RA initiation is 4(-62~57)days. No significant difference was observed in the overall response rates between the TPO-RA group and the IST group at any of the assessed time points (3-month: 32.26% vs. 30.19%, 6-month: 58.06% vs. 43.4%, 9-month: 58.62% vs. 58.49%, 12-month: 60.71% vs. 62.26%, all P > 0.05). Notably, the complete response rate at 9 months was significantly higher in the TPO-RA group (34.48% vs. 15.09%, P = 0.043), while no statistical difference between the two groups at the remaining time points (3-month: 3.23% vs. 3.77% , 6-month: 19.35% vs. 15.09%, 12-month: 35.71% vs. 28.3%; all P > 0.05). Similarly, The two groups exhibited comparable median times to achieve red blood cell and platelet transfusion independence (51.5 [12–346] vs. 44 [0–270] days; 54.4 [12–382] vs. 44 [0–273] days, all P > 0.05). Patients in the TPO-RA group and the IST group were followed up for a median of 33.73 (7.53–91.66) months and 106.87 (27.3–134.73) months, respectively. There were no significant intergroup differences in event free survival (EFS) rate or overall survival (OS) rate (3-year EFS: 65.6% ± 8.9% vs. 64.2% ± 6.6%, P = 0.977; 3-year OS: 100% vs. 96.2% ± 2.6%, P = 0.28). Multivariate logistic regression analysis revealed that avatrombopag was associated with higher 3 month and 6 month overall response rates (OR: 6.565 [1.336–32.265], P = 0.021;OR: 24.651 [1.988–305.723], P = 0.013); eltrombopag was also associated with a higher 6 month overall response rate (OR: 12.825 [1.087–151.242], P = 0.043). However, neither of them was associated with long term response rates or overall response rates. Additionally, a higher hemoglobin concentration at diagnosis was associated with higher 3 month overall response rate (OR: 1.059 [1.004–1.118], P = 0.037), and female patients had inferior treatment responses compared with male patients at 12 month overall response rate (OR: 0.339 [0.119–0.963], P = 0.042).

Conclusion   Adding TPO-RA to standard IST as first-line therapy yields favorable effects on complete response rate at 9 months but not overall response rate and overall prognosis among children with acquired SAA. Additionally, eltrombopag and avatrombopag can improve the early response rate of IST.

Hui Lv, N/A: No relevant conflicts of interest to declare.